Circulating inflammatory ILC2s as a biomarker of gastric cancer progression
Ryan N. O’Keefe, Kiruthiga Raghunathan, Moritz F. Eissmann, David Baloyan, Ashleigh R. Poh, Megan O'Brien, Edgar Clapdorp, Shoukat Afshar‐Sterle, Richard M. Locksley, Matthias Ernst, Michael Büchert
This study identifies circulating inflammatory ILC2s as a biomarker for gastric cancer progression, showing their association with disease severity and potential for early detection.
bioRxiv · May 1, 2026 · PreprintCancer Biology